DBV Technologies (NASDAQ:DBVT) Stock Passes Above 50 Day Moving Average – What’s Next?

DBV Technologies S.A. (NASDAQ:DBVT) shares passed above its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $3.91 and traded as high as $4.46. DBV Technologies shares last traded at $4.39, with a volume of 6,288 shares traded.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on DBVT. StockNews.com began coverage on DBV Technologies in a report on Tuesday. They issued a “hold” rating for the company. HC Wainwright boosted their price objective on shares of DBV Technologies from $25.00 to $35.00 and gave the company a “buy” rating in a research report on Thursday, October 24th. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $10.00 price target on shares of DBV Technologies in a research note on Friday, January 10th.

DBV Technologies Stock Performance

The firm’s 50 day moving average is $3.95 and its 200 day moving average is $3.84. The stock has a market cap of $88.45 million, a P/E ratio of -0.96 and a beta of 0.67.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in DBV Technologies stock. Boxer Capital Management LLC acquired a new position in DBV Technologies S.A. (NASDAQ:DBVT) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 50,000 shares of the company’s stock, valued at approximately $154,000. Boxer Capital Management LLC owned 0.24% of DBV Technologies as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.